r960-41ef5de21fe6c5c71a1752e1aa46c92d.jpg


SAN FRANCISCO —The biotech industry converges this week for its largest annual conference amid an uncertain new federal policy environment under President-elect Trump.

J.P. Morgan’s Health Investor Conference, the industry’s biggest annual networking event, will feature presentations Monday through Thursday from more than 450 companies including the biggest biotech, medical device and drug companies, and some provider groups and insurers.

New drug developments and revenue forecasts will be a big part of the week. But this year, companies face the prospect of Congress repealing much of the Affordable Care Act and a Republican president who has taken a hardline stance on high drug prices — a much different backdrop for the industry than had Hillary Clinton won the election.

Biotech companies seeking faster drug approvals are also closely watching Trump’s appointment to lead the FDA. One likely prospect is Jim O’Neill, a libertarian who has called for approving new medications for sale before fully determining their effectiveness.

And the conference convenes as the FDA starts implementing a bipartisan medical cures bill Congress passed last month, legislation aimed at speeding the approval of new and breakthrough drugs. The measure included funding for the cancer “moonshot” initiative spearheaded by Vice President Joe Biden, who will speak at the conference on Monday.

As executives present their new innovations over the course of the week, the increasingly high cost of drugs will be the policy elephant in the room. Major life-extending medical advances over the past decade have contributed to an environment in the U.S. of steeply priced drugs, a topic of increasing discomfort especially to companies that have come under fire for dramatically hiking the price of existing medications and devices.

Trump has said little since the election on how he’d propose to tackle drug prices, but during his campaign he indicated it was a top concern, and even advocated for allowing Medicare to start negotiating lower prices with drug makers — an idea unpopular in the pharmaceutical industry and among most Republicans.

And Congress’ likely repeal of Obamacare will affect everyone, most directly insurers who sell marketplace and Medicaid plans, but also drug makers and providers who care for the law’s newly-insured.

Any big policy changes that shift the number of uninsured Americans or change the type of coverage they have will prompt a ripple effect through the industry. And insurers and medical device makers are fearful Republicans will decide against repealing taxes embedded within the law.

Sylvia Burwell: Obamacare repeal to impact states

Also from the Washington Examiner

HHS secretary will deliver final address on Monday at the National Press Club.

01/09/17 6:00 AM

Andy Slavitt, acting administrator for the Centers for Medicare and Medicaid Services, will likely address Obamacare repeal in his J.P. Morgan address slated for Monday night. His agency, which oversees the federal Healthcare.gov marketplace, has been working to ensure open enrollment continues smoothly until the end of the month even with repeal efforts underway.

Other presenters this week include:

Valeant Pharmaceuticals and Mylan, whose executives testified before Congress last year on the prices they’re charging for some drugs and devices, including Mylan’s EpiPen.

Molina Healthcare, Wellcare Health Plans and Blue Cross Blue Shield of Michigan, three smaller health insurers who have invested heavily in the Obamacare marketplaces.

Cigna Corp., a major insurer which had originally planned to expand its participation to Obamacare marketplaces in 10 states this year, but is remaining in just seven due to financial losses.

Trump team prepares to defend nominees against onslaught

Also from the Washington Examiner

Transition hopes to defuse the searing rhetoric that will be hurled at Trump’s nominees

01/09/17 12:01 AM

Dems planning stall tactics for Trump's Cabinet picks this week

Top Story

A slew of nominees will appear before the Senate.

01/09/17 12:01 AM



Source link

About the Author:

Leave a Reply